



# Toxicological Profile for N-Nitrosodimethylamine (NDMA)

April 2023



U.S. Department of Health and Human Services  
Agency for Toxic Substances and Disease Registry

CS274127-A

## **DISCLAIMER**

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

## FOREWORD

This toxicological profile is prepared in accordance with guidelines\* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Robin Ikeda, MD, MPH

Acting Director, National Center for Environmental Health and Agency for Toxic Substances and Disease Registry Centers for Disease Control and Prevention



Christopher M. Reh, Ph.D.

Associate Director  
Agency for Toxic Substances and Disease Registry  
Centers for Disease Control and Prevention

### \*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

## VERSION HISTORY

Date	Description
April 2023	Final toxicological profile released
January 2022	Draft for public comment toxicological profile released
December 1989	Final toxicological profile released

## CONTRIBUTORS & REVIEWERS

### CHEMICAL MANAGER TEAM

Custodio Muianga, M.P.H., Ph.D., C.H.M.M. (Lead)	Heather Carlson-Lynch, M.S., D.A.B.T.
Nickolette Roney, M.P.H.	Mario Citra, Ph.D.
Jennifer Przybyla, Ph.D.	Claire Heit, Ph.D.
ATSDR, Office of Innovation and Analytics, Toxicology Section, Atlanta, GA	SRC, Inc., North Syracuse, NY

### REVIEWERS

#### **Interagency Minimal Risk Level Workgroup:**

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

#### **Additional reviews for science and/or policy:**

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA/Center for Public Health and Environmental Assessment (CPHEA); EPA/Office of Water (OW).

### PEER REVIEWERS

1. Paul Westerhoff; Regents Professor; School of Sustainable Engineering and the Built Environment; Arizona State University; Tempe, Arizona
2. Steve Hrudehy; Ph.D. Professor Emeritus; Department of Laboratory Medicine and Pathology; University of Alberta; Edmonton, Alberta, Canada
3. David Eastmond; Professor and Toxicologist; Department of Molecular Cell and Systems Biology; University of California Riverside; Riverside, California

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

## CONTENTS

DISCLAIMER .....	ii
FOREWORD .....	iii
VERSION HISTORY .....	v
CONTRIBUTORS & REVIEWERS .....	vi
CONTENTS .....	vii
LIST OF FIGURES .....	ix
LIST OF TABLES .....	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH .....	1
1.1 OVERVIEW AND U.S. EXPOSURES .....	1
1.2 SUMMARY OF HEALTH EFFECTS .....	2
1.3 MINIMAL RISK LEVELS (MRLs) .....	5
CHAPTER 2. HEALTH EFFECTS .....	8
2.1 INTRODUCTION .....	8
2.2 DEATH .....	34
2.3 BODY WEIGHT .....	37
2.4 RESPIRATORY .....	38
2.5 CARDIOVASCULAR .....	38
2.6 GASTROINTESTINAL .....	39
2.7 HEMATOLOGICAL .....	40
2.8 MUSCULOSKELETAL .....	41
2.9 HEPATIC .....	41
2.10 RENAL .....	46
2.11 DERMAL .....	47
2.12 OCULAR .....	47
2.13 ENDOCRINE .....	48
2.14 IMMUNOLOGICAL .....	48
2.15 NEUROLOGICAL .....	49
2.16 REPRODUCTIVE .....	49
2.17 DEVELOPMENTAL .....	50
2.18 OTHER NONCANCER .....	51
2.19 CANCER .....	51
2.20 GENOTOXICITY .....	70
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS .....	79
3.1 TOXICOKINETICS .....	79
3.1.1 Absorption .....	80
3.1.2 Distribution .....	82
3.1.3 Metabolism .....	85
3.1.4 Excretion .....	88
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models .....	90
3.1.6 Animal-to-Human Extrapolations .....	90
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE .....	91
3.3 BIOMARKERS OF EXPOSURE AND EFFECT .....	95
3.3.1 Biomarkers of Exposure .....	96

3.3.2	Biomarkers of Effect .....	97
3.4	INTERACTIONS WITH OTHER CHEMICALS .....	98
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION .....		102
4.1	CHEMICAL IDENTITY .....	102
4.2	PHYSICAL AND CHEMICAL PROPERTIES .....	102
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE .....		104
5.1	OVERVIEW .....	104
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL .....	105
5.2.1	Production .....	105
5.2.2	Import/Export.....	106
5.2.3	Use .....	106
5.2.4	Disposal.....	107
5.3	RELEASES TO THE ENVIRONMENT .....	107
5.3.1	Air .....	108
5.3.2	Water.....	110
5.3.3	Soil .....	110
5.4	ENVIRONMENTAL FATE .....	110
5.4.1	Transport and Partitioning.....	111
5.4.2	Transformation and Degradation .....	111
5.5	LEVELS IN THE ENVIRONMENT.....	113
5.5.1	Air .....	114
5.5.2	Water.....	116
5.5.3	Sediment and Soil .....	119
5.5.4	Other Media .....	119
5.6	GENERAL POPULATION EXPOSURE.....	127
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES .....	129
CHAPTER 6. ADEQUACY OF THE DATABASE.....		131
6.1	INFORMATION ON HEALTH EFFECTS.....	131
6.2	IDENTIFICATION OF DATA NEEDS .....	133
6.3	ONGOING STUDIES.....	138
CHAPTER 7. REGULATIONS AND GUIDELINES .....		139
CHAPTER 8. REFERENCES .....		141
APPENDICES		
APPENDIX A.	ATSDR MINIMAL RISK LEVEL WORKSHEETS .....	A-1
APPENDIX B.	LITERATURE SEARCH FRAMEWORK FOR NDMA .....	B-1
APPENDIX C.	USER'S GUIDE .....	C-1
APPENDIX D.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS .....	D-1
APPENDIX E.	GLOSSARY .....	E-1
APPENDIX F.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS .....	F-1



## LIST OF FIGURES

1-1. Health Effects Found in Animals Following Oral Exposure to N-Nitrosodimethylamine (NDMA) .....	3
1-2. Summary of Sensitive Targets of N-Nitrosodimethylamine (NDMA) – Oral .....	6
2-1. Overview of the Number of Studies Examining N-Nitrosodimethylamine (NDMA) Health Effects.....	11
2-2. Levels of Significant Exposure to N-Nitrosodimethylamine – Inhalation .....	14
2-3. Levels of Significant Exposure to N-Nitrosodimethylamine – Oral .....	30
3-1. Metabolism of N-Nitrosodimethylamine.....	86
5-1. Number of NPL Sites with NDMA Contamination.....	104
6-1. Summary of Existing Health Effects Studies on N-Nitrosodimethylamine (NDMA) by Route and Endpoint.....	132

## LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for N-Nitrosodimethylamine (NDMA) .....	7
2-1. Levels of Significant Exposure to N-Nitrosodimethylamine – Inhalation .....	12
2-2. Levels of Significant Exposure to N-Nitrosodimethylamine – Oral .....	16
2-3. Overview of Epidemiological Studies of Ranitidine Use and Cancers .....	56
2-4. Overview of Epidemiological Studies of N-Nitrosodimethylamine Dietary Intake and Cancers .....	59
2-5. Genotoxicity of N-Nitrosodimethylamine <i>In Vitro</i> .....	70
2-6. Genotoxicity of N-Nitrosodimethylamine <i>In Vivo</i> .....	74
3-1. Maximum Blood Concentration and Time to Maximum in Animals Exposed to N-Nitrosodimethylamine (NDMA) by Oral Administration .....	81
3-2. Species Differences in Steady-State Volume of Distribution for Unmetabolized N-Nitrosodimethylamine (NDMA) ( $V_{ss}$ ) after Intravenous Exposure .....	83
4-1. Chemical Identity of N-Nitrosodimethylamine .....	102
4-2. Physical and Chemical Properties of N-Nitrosodimethylamine .....	102
5-1. Facilities that Produce, Process, or Use N-Nitrosodimethylamine .....	106
5-2. Releases to the Environment from Facilities that Produce, Process, or Use N-Nitrosodimethylamine .....	108
5-3. Emissions of N-Nitrosodimethylamine (NDMA) to Air Reported to the National Emissions Inventory .....	109
5-4. Lowest Limit of Detection Based on Standards .....	114
5-5. N-Nitrosodimethylamine (NDMA) Levels in Water, Soil, and Air of National Priorities List (NPL) Sites .....	114
5-6. Detection of N-Nitrosodimethylamine in Foods and Beverages .....	120
5-7. Estimates of Daily Intake of N-Nitrosodimethylamine (NDMA) from Endogenous and Exogenous Sources for Selected Age Groups (ng/kg Body Weight/Day) .....	128
7-1. Regulations and Guidelines Applicable to N-Nitrosodimethylamine (NDMA) .....	139